

Volume 39

**Advances in
Internal
Medicine®**

**Schrier • Abboud
Baxter • Fauci**

Advances in Internal Medicine®

Editor

Robert W. Schrier, M.D.

Professor and Chairman, Department of Medicine, University of Colorado School of Medicine; Attending Physician, Renal Division, University Hospital, University of Colorado Health Sciences Center, Denver, Colorado

Associate Editors

François M. Abboud, M.D.


Edith King Pearson Professor of Medicine, Head, Department of Internal Medicine, University of Iowa College of Medicine; Director of Cardiovascular Research Center, University of Iowa Hospitals and Clinics, Iowa City, Iowa

John D. Baxter, M.D.

Professor of Medicine, University of California; Director, Metabolic Research Unit and Chief, Division of Endocrinology, Moffitt Hospital, San Francisco, California

Anthony S. Fauci, M.D.*

Chief, Laboratory of Immunoregulation, Director, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland



*Dr. Fauci edited this book in his private capacity and no official endorsement or support by the National Institutes of Health is intended or should be inferred.

M Mosby

Volume 39 • 1994

St. Louis Baltimore Boston Chicago London Madrid Philadelphia Sydney Toronto



Dedicated to Publishing Excellence

Vice President, Continuity Publishing: Kenneth H. Killion

Sponsoring Editor: Kelly Poirier

Project Manager: Denise Dungey

Project Supervisor: Maria Nevinger

Production Editor: Laura Pelehach

Staff Support Administrator: Barbara M. Kelly

Copyright © 1994 by Mosby—Year Book, Inc.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without prior written permission from the publisher.

Permission to photocopy or reproduce solely for internal or personal use is permitted for libraries or other users registered with the Copyright Clearance Center, provided that the base fee of \$4.00 per chapter plus \$.10 per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, MA 01970. This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collected works, or for resale.

Printed in the United States of America

Composition by The Clarinda Company

Printing/binding by The Maple-Vail Book Manufacturing Group

Mosby—Year Book, Inc.

11830 Westline Industrial Drive

St. Louis, Missouri 63146

Editorial Office:

Mosby—Year Book, Inc.

200 North LaSalle Street

Chicago, Illinois 60601

International Standard Serial Number: 0065–2822

International Standard Book Number: 0–8151–83127

Contributors

William T. Abraham, M.D.

Instructor of Medicine, University of Colorado, School of Medicine, Denver, Colorado

Pamela W. Anderson, M.D.

Assistant Professor of Medicine, University of Southern California School of Medicine, Los Angeles

John H. Bloor, M.D., Ph.D.

Instructor, University of Colorado School of Medicine, Department of Medicine, Division of Gastroenterology and Hepatobiliary Research Center, Staff Physician, Denver Veterans Administration Medical Center, Department of Medicine, Division of Gastroenterology, Denver, Colorado

Vreny A. Briner, M.D.

Department of Medicine, University Hospital Bern, Bern, Switzerland

Jay N. Cohn, M.D.

Professor of Medicine, Head, Cardiovascular Division, Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota

Pamela S. Douglas, M.D.

Charles A. Dana Research Institute, Harvard-Thorndike Laboratory of the Department of Medicine (Cardiovascular Division), Associate Professor of Medicine, Harvard Medical School, Director, Non-Invasive Cardiology, Beth Israel Hospital, Boston, Massachusetts

David P. Faxon, M.D.

Professor of Medicine, University of Southern California School of Medicine, Chief, Division of Cardiology, University of Southern California Medical Center, Los Angeles, California

Eric R. Fearon, M.D., Ph.D.

Assistant Professor of Pathology and Biology, Boyer Center for Molecular Medicine, Yale University School of Medicine, New Haven, Connecticut

Gary S. Hoffman, M.D.

Head, Vasculitis and Related Diseases Section, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland; Chairman, Department of Rheumatic and Immunologic Diseases, Cleveland Clinic Foundation, Cleveland, Ohio

Jay H. Hoffnagle, M.D.

Director, Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland

Willa A. Hsueh, M.D.

Professor of Medicine, University of Southern California School of Medicine, Los Angeles, California

Bruce E. Johnson, M.D.

Chief, Lung Cancer Biology Section, Navy Medical Oncology Branch, National Cancer Institute, National Naval Medical Center, Bethesda, Maryland

John P. Kane, M.D., Ph.D.

Professor of Medicine, Professor of Biochemistry and Biophysics, Cardiovascular Research Institute, University of California, San Francisco, School of Medicine, San Francisco, California

Paul Katz, M.D.

Professor and Vice Chairman, Department of Medicine, Chief, Division of Rheumatology, Immunology and Allergy, Georgetown University Medical Center, Washington, D.C.

Michael J. Kelley, M.D.

Medical Staff Fellow, Navy Medical Oncology Branch, National Cancer Institute, National Naval Medical Center, Bethesda, Maryland

Spencer H. Kubo, M.D.

Associate Professor of Medicine, Director, Heart Failure—Heart Transplantation Program, Cardiovascular Division, Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota

T.F. Lüscher, M.D.

Professor, Clinical Pharmacology, University Hospital Basel, Basel, Switzerland

Mary J. Malloy, M.D.

Clinical Professor of Medicine and Pediatrics, Cardiovascular Research Institute, University of California, San Francisco, School of Medicine, San Francisco, California

John E. Mapoles, Ph.D.

Assistant Professor, University of Colorado School of Medicine, Department of Microbiology, Hepatobiliary Research Center; Research Biologist, Denver Veterans Administration Medical Center, Denver, Colorado

Adolph Mares, Jr., M.D.

Fellow, Section of Cardiology, Baylor College of Medicine, Houston, Texas

E.R. McFadden, Jr., M.D.

Argyl J. Beams Professor of Medicine, Director, Airway Disease Center, Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio

Peter Oettgen, M.D.

Charles A. Dana Research Institute, Harvard-Thorndike Laboratory of the Department of Medicine (Cardiovascular Division), Instructor of Medicine, Harvard Medical School, Codirector, Cardiovascular Health and Lipid Center, Beth Israel Hospital, Boston, Massachusetts

Allan I. Pack, M.D., Ch.B., Ph.D.

Professor of Medicine, Pulmonary and Critical Care Division, Director, Center for Sleep and Respiratory Neurobiology, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania

Thomas C. Quinn, M.D.

Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland; Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland

Robert Roberts, M.D.

Professor of Medicine and Cell Biology, Chief of Cardiology, Baylor College of Medicine; Director, Bugher Foundation Center for Molecular Cardiology, Houston, Texas

Anne Rompalo, M.D.

Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore City Health Department, Sexually Transmitted Diseases Clinics, Baltimore, Maryland

Thomas J. Ryan, M.D.

Professor of Medicine, Evans Department of Clinical Research and Department of Medicine, Chief of Cardiology, Section of Cardiology, University Hospital, Boston University Medical Center, Boston, Massachusetts

Peter N. Schlegel, M.D.

Assistant Professor of Urology, James Buchanan Brady Foundation, Department of Urology, The New York Hospital-Cornell Medical Center, New York; Staff Scientist, The Population Council, Center for Biomedical Research, New York, New York

Steven M. Schnittman, M.D.

Chief, Medical Branch, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland

Francis R. Simon, M.D.

Professor, University of Colorado School of Medicine, Department of Medicine, Division of Gastroenterology, Director, Hepatobiliary Research Center; Staff Physician, Department of Medicine, Division of Gastroenterology, Denver Veterans Administration Medical Center, Denver, Colorado

Andrea T. Slotkoff, M.D.

Post Doctoral Fellow, Division of Rheumatology, Immunology and Allergy, Department of Medicine, Georgetown University Medical Center, Washington, D.C.

J. Blake Tyrrell, M.D.

Metabolic Research Unit, Department of Medicine, University of California, San Francisco School of Medicine, San Francisco, California

Jonathan Zenilman, M.D.

Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore City Health Department, Sexually Transmitted Diseases Clinics, Baltimore, Maryland

Publisher's Preface

Advances in Internal Medicine®, volume 39, marks the beginning of a new era of editorship for this publication. We at Mosby hope you will join us in welcoming Robert W. Schrier, M.D., Professor and Chairman of the Department of Medicine at the University of Colorado School of Medicine, to his new role as Editor-in-Chief along with Associate Editors, Francois Abboud, M.D., Edith King Pearson Professor of Medicine and Head of the Department of Internal Medicine at the University of Iowa College of Medicine; John D. Baxter, M.D., Professor of Medicine at the University of California; and Anthony S. Fauci, M.D., Chief of the Laboratory of Immunoregulation and Director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health.

Under the stellar leadership of Drs. Schrier, Abboud, Baxter, and Fauci, we are certain that *Advances in Internal Medicine*® will continue to provide readers with insightful, important, thought-provoking, and clinically relevant information. Again, welcome.

MOSBY—YEAR BOOK, INC.

Contents

Contributors	vii
Publisher's Preface	xi
Role of Vascular Endothelial Abnormalities in Clinical Medicine: Atherosclerosis, Hypertension, Diabetes, and Endotoxemia.	
<i>By Vreny A. Briner and T.F. Lüscher</i>	1
Endothelium-Derived Relaxing Factors	1
Endothelium-Derived Contracting Factors	3
Atherosclerosis.	3
Vascular Smooth Muscle Cell Growth in the Blood Vessel	5
Hypoxia, Ischemia, and Reperfusion	6
Coronary Bypass Function	6
Hypertension	7
Diabetes	9
Structural Changes in the Vessel Wall and Kidney	9
Endotoxemia	11
Release of Vasoactive Substances	11
Endotoxin-Induced Cytotoxicity	12
Effects of Endotoxin Exposure via Different NO Synthases.	13
Implications for Treatment	14
Body Fluid Volume Regulation in Health and Disease.	
<i>By William T. Abraham and Robert W. Schrier</i>	23
Afferent Mechanisms Involved in Body Fluid Volume Regulation	23
The Concept of Effective Blood Volume.	24
The Integrity of the Arterial Circulation as the Determinant of Effective Blood Volume	24
Afferent Volume Receptors	25
Efferent Mechanisms Involved in Body Fluid Volume Regulation	27
Cardiac Failure	30
Cirrhosis	33
Pregnancy	37
Summary	41

Alcoholic Liver Disease: New Concepts of Pathogenesis and Treatment.

By John H. Bloor, John E. Mapoles, and Francis R. Simon **49**

Absorption, Distribution, and Elimination of Ethanol	50
Metabolism of Ethanol	50
Alcohol and Aldehyde Dehydrogenases	51
Other Routes for Ethanol Metabolism	54
Pathological Effects of Ethanol and Ethanol Metabolism	56
Ethanol	56
Acetaldehyde	57
Genetics of Alcoholic Liver Disease	59
Treatment of Alcoholic Liver Disease	62
Nutritional Factors	63
Insulin and Glucagon Infusion	65
Pharmacologic Agents	67
Surgery	72
Recommendations	77
Future Prospects	78

Genetic Mechanisms of Solid Tumor Oncogenesis.

By Michael J. Kelley and Bruce E. Johnson **93**

Tumor Suppressor Genes and Proto-oncogenes	94
The p53 Gene	96
The ras Gene Family	103
The Adenomatous Polyposis Coli Gene	105
The Mutated in Colorectal Cancer Gene	107
The Retinoblastoma Gene	108
The Deleted in Colon Cancer Gene	109
Putative Tumor Suppressor Gene(s) on Chromosome 3p	111
The NF1 Gene	113
Summary	113

Molecular Genetic Studies of the Adenoma-Carcinoma Sequence.

By Eric R. Fearon **123**

Natural History of Colon and Rectal Cancer	124
Clinical and Histopathological Studies	124
Inherited Syndromes Predisposing to Colorectal Cancer	125
The Genetics of Inherited Colorectal Cancer	128
Familial Polyposis and the APC Gene	128
Heritable Nonpolyposis Colorectal Cancer	130
Somatic Genetic Alterations Underlying the Adenoma-Carcinoma Sequence	131

Somatic Mutations and the Clonal Origin of Human Cancer Cells	131
Alterations in Oncogenes in the Adenoma-Carcinoma Sequence.	132
Tumor Suppressor Gene Alterations in the Adenoma-Carcinoma Sequence	134
A Genetic Model for the Adenoma-Carcinoma Sequence	136
Clinical Applications of Molecular Genetic Studies	139
Summary	143
Sexually Transmitted Diseases: Advances in Diagnosis and Treatment.	
By Thomas C. Quinn, Jonathan Zenilman, and Anne Rompalo	149
Epidemiology	149
<i>Chlamydia trachomatis</i>	152
<i>Neisseria gonorrhoeae</i>	159
Pelvic Inflammatory Disease	162
Syphilis	165
Genital Human Papillomavirus Infections	167
Genital Herpes	172
Hepatitis B Virus	176
Hepatitis C Virus	177
Bacterial Vaginosis	178
<i>Trichomonas vaginalis</i>	181
Human Immunodeficiency Virus and Sexually Transmitted Diseases	182
Epidemiology and Control Issues in Sexually Transmitted Diseases	183
Approach to the Patient With Rheumatoid Arthritis.	
Andrea T. Slotkoff and Paul Katz	197
Pathogenesis	198
Etiology	198
Immunogenetics	199
Immunopathology	200
Basic Approach	201
Diagnosis	201
General Management	202
First-Line Drug Therapy	205
Nonsteroidal Anti-inflammatory Drugs.	205
Corticosteroids.	207

Second-Line Therapy	209
Gold Salts	209
Antimalarials	211
D-Penicillamine	212
Sulfasalazine	213
Methotrexate	215
Azathioprine.	218
Cyclophosphamide	220
Cyclosporine	221
Immunotherapy	223
Combination Therapy	226
Inverting the Pyramid	227
Summary	228
Therapy of Acute and Chronic Viral Hepatitis.	
<i>By Jay H. Hoofnagle</i>	241
Acute Viral Hepatitis	241
Chronic Viral Hepatitis	246
Chronic Hepatitis B.	247
Chronic Delta Hepatitis	257
Chronic Hepatitis C.	260
Summary	266
Emerging Concepts in the Management of Vasculitic Diseases.	
<i>By Gary S. Hoffman and Anthony S. Fauci</i>	277
The Treatment of Systemic Vasculitis	277
Initial Therapeutic Interventions	279
Chronic Therapy.	291
Immunotherapy/Biological Agents	296
Immunoregulation and Recombinant Proteins.	297
Human Immunodeficiency Virus and Acquired Immunodeficiency Syndrome: An Update.	
<i>By Steven M. Schnittman and Anthony S. Fauci</i>	305
Scope of the Epidemic and Epidemiology	305
Virology/Pathogenesis	309
Viral Life Cycle	309
Viral Expression and Latency	310
CD4 Positive T-Cell Depletion and Dysfunction	313
Role of Monocytes/Macrophages.	316
Role of B Lymphocytes	317
Role of Bone Marrow-Derived Dendritic Cells.	318

Role of Follicular Dendritic Cells in Lymphoid Organ HIV Pathogenesis	318
Therapeutics	318
Antiretroviral Therapy	318
Microbial Resistance to Antiretrovirals	321
ZDV Therapy in Minorities With HIV	322
Therapeutic Vaccines	323
Opportunistic Infections	327
Vaccines	330
Special Topics	338
CDC Revised Classification System for HIV Infection and Disease in Adolescents and Adults	338
Special Problems of HIV Infection in Women	338
Tuberculosis, Multi-drug Resistant Tuberculosis, and HIV	339
Gene Therapy	342
Summary and Conclusions	345
Evolving Concepts in the Pathogenesis and Management of Asthma.	
By E.R. McFadden, Jr.	357
Asthma: Magnitude of the Problem.	358
Asthma and Airway Reactivity.	359
Asthma and Airway Inflammation	360
Pharmacology of Asthma	365
Adrenergic Agonists.	365
Controversies Surrounding the Use of β_2 -Agonists	367
Do β -Agonists Worsen Lung Function or Unfavorably Alter Asthma?	367
Methylxanthines	369
Anticholinergics	371
Glucocorticoids	372
Antiinflammatory Agents	375
Ancillary Antiinflammatory Therapy	376
Mediator Antagonists	377
Guidelines for Therapy	378
Management of Chronic Asthma.	379
The Techniques of Molecular Biology and Their Application to the Cardiomyopathies.	
By Adolph Mares, Jr. and Robert Roberts	395
Overview of Molecular Genetics and Linkage Analysis	396
Chromosomal Mapping Using DNA Markers and Linkage Analysis	396

Axioms Fundamental to Linkage Analysis	401
Role of the Clinician	402
Techniques of Molecular Biology	403
Isolation of DNA	404
Transformed Lymphoblast Cell Lines	404
Digestion of DNA With Restriction Endonucleases	405
Separation and Identification of DNA Fragments by Gel Electrophoresis.	405
Southern, Northern, and Western Blotting	406
Generation of a cDNA from mRNA.	406
DNA Cloning	408
Development of Gene Libraries	410
Nucleic Acid Sequencing.	410
Polymerase Chain Reaction.	410
Chromosomal Walking and Jumping to Isolate Genes	413
Techniques to Screen for Mutations	413
The Molecular Genetics of Various Cardiomyopathies	414
Medical Management of Coronary Artery Disease After Angioplasty and Thrombolytic Therapy.	
By David P. Faxon and Thomas J. Ryan	435
Medical Management After Percutaneous Transluminal Coronary Angioplasty	435
In-Hospital Management After Angioplasty	435
Out-of-Hospital Management	440
Medical Management After Thrombolytic Therapy	445
In-Hospital Management	445
Long-Term Management.	457
Coronary Artery Disease in Women: Diagnosis and Prevention.	
By Peter Oettgen and Pamela S. Douglas	467
Epidemiology	467
Diagnosis.	469
Gender Bias	473
Risk Factor Modification	475
Conclusion	481
Approach to Treatment of the Patient With Heart Failure in 1994.	
Spencer H. Kubo and Jay N. Cohn	485
Treatment Endpoints and Patient Subgroups	485
Patients With Established Signs and Symptoms of Heart Failure—Group B	487
Diuretics	487

Digitalis	490
Vasodilators	493
Converting Enzyme Inhibitors	495
Adjunctive Therapy	497
Patients With Refractory or Persistent Signs and Symptoms of Heart Failure—Group C	500
Use of Intravenous Vasodilators and Inotropic Agents in the Intensive Care Unit	500
Heart Transplantation	502
Patients With Asymptomatic Left Ventricular Dysfunction—Group A	506
Obstructive Sleep Apnea.	
<i>By Allan I. Pack</i>	517
Varieties of Disease and Definitions	518
Pathogenesis of Obstructive Sleep Apnea	520
Anatomical Component	520
Neural Component	524
Diagnosis of Sleep Apnea	525
Prevalence of Obstructive Sleep Apnea	528
Mortality and Morbidity From Obstructive Sleep Apnea	530
Mortality	530
Driving Accidents	532
Hypertension and Other Cardiovascular Problems	533
Treatment of Obstructive Sleep Apnea	537
Underlying Causes and General Measures	537
Pharmacotherapy	538
Nasal CPAP	539
Intraoral Devices	544
Surgical Treatment	545
Staged Approach to Therapy	550
Conclusion	552
Medical Management of Prostatic Diseases.	
<i>By Peter N. Schlegel</i>	569
Benign Prostatic Hypertrophy	569
Overview and Treatment Options	569
Patient Evaluation	571
Treatment Options	576
Prostate Cancer	586
Overview	586
Treatment by Stage	587
Hormonal Therapy	590

Nonhormonal Therapy for Androgen-Independent Prostate Cancer.	596
Summary	597
Medical Management of Hyperlipidemic States.	
<i>By Mary J. Malloy and John P. Kane.</i>	603
Relationship of Lipoproteins to Atherogenesis.	604
High Density Lipoproteins and the Risk of Coronary Heart Disease	606
Family History—A Risk Factor for Coronary Disease.	607
Relationship of Lipemia to Pancreatitis	608
Mechanisms of Atherogenesis	608
Lipoprotein Metabolism	610
Genetic Disorders of Lipoprotein Metabolism	611
Clinical Differentiation of Lipoprotein Disorders	613
The Decision to Treat	614
Diet Modification.	616
Drug Treatment	617
Drug Combination Therapy	622
Possible Untoward Consequences of Lipid-Lowering Therapy	623
Evidence of Regression of Coronary Lesions	624
Hypertension and Diabetic Vascular Complications.	
<i>By Pamela W. Anderson and Willa A. Hsueh.</i>	633
Background.	633
Effects of Diabetes and Hypertension on Vascular Biology.	634
Atherosclerosis.	638
Diabetic Nephropathy	640
Diabetic Retinopathy	642
Prognostic and Therapeutic Implications.	643
A View Toward the Future	650
Evaluation of the Hypothalamic-Pituitary-Adrenal Axis: Importance in Steroid Therapy, AIDS, and Other Stress Syndromes.	
<i>By John D. Baxter and J. Blake Tyrrell</i>	667
The Hypothalamic-Pituitary-Adrenal Axis	669
Abnormalities of the Hypothalamic-Pituitary-Adrenal Axis	671
Hyperfunction	671
Hypofunction	674
Indications for Evaluation of the Axis	678

Clinical Evaluation: History and Physical Examination	679
Clinical Evaluation: Laboratory Tests	680
Basal Measurements	681
Stimulation of the Hypothalamic-Pituitary-Adrenal Axis	683
Suppression Testing.	686
Diagnosis of Adrenal Insufficiency	688
Diagnosis of Glucocorticoid Excess	689
Perspective	691
Index	697